Insights

Expanding Vaccine Portfolio Replicate Bioscience's development of srRNA vaccines for HIV and malaria presents an opportunity to collaborate on advanced vaccine delivery technologies and expanding infectious disease vaccine capabilities, appealing to organizations involved in global health initiatives.

Strategic Collaborations The multi-year research partnership with Novo Nordisk targeting cardiometabolic diseases indicates strong potential for joint development programs and licensing deals with pharmaceutical companies looking to leverage innovative RNA platform therapies.

Emerging Therapeutics Replicate's focus on self-replicating RNA for autoimmune, infectious, and oncology applications suggests opportunities to provide contract research, custom vector development, or licensing agreements for biotech firms targeting these high-growth therapeutic areas.

Funding and Revenue Growth With revenue estimates between $10M to $25M and recent product launches like the srRNA rabies vaccine, there is potential to engage with organizations interested in funding or acquiring innovative RNA-based platforms and accelerating commercialization efforts.

Technological Differentiation Replicate's proprietary srRNA technology, characterized by better performance over linear mRNA, offers chances to partner on joint R&D projects, increase licensing opportunities, or expand customized vector library sales to biotech and pharma companies seeking to enhance their therapeutic pipelines.

Replicate Bioscience, Inc. Tech Stack

Replicate Bioscience, Inc. uses 8 technology products and services including RSS, WordPress, JSON-LD, and more. Explore Replicate Bioscience, Inc.'s tech stack below.

  • RSS
    Content Management System
  • WordPress
    Content Management System
  • JSON-LD
    Javascript Frameworks
  • ScrollReveal
    Javascript Libraries
  • Priority Hints
    Performance
  • WP Engine
    Platform As A Service
  • Google Tag Manager
    Tag Management
  • Nginx
    Web Servers

Media & News

Replicate Bioscience, Inc.'s Email Address Formats

Replicate Bioscience, Inc. uses at least 1 format(s):
Replicate Bioscience, Inc. Email FormatsExamplePercentage
FLast@replicatebioscience.comJDoe@replicatebioscience.com
100%

Frequently Asked Questions

Where is Replicate Bioscience, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc.'s main headquarters is located at 10210 Campus Point Drive #150 San Diego, California 92121 United States. The company has employees across 1 continents, including North America.

What is Replicate Bioscience, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc.'s official website is replicatebioscience.com and has social profiles on LinkedInCrunchbase.

What is Replicate Bioscience, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Replicate Bioscience, Inc. have currently?

Minus sign iconPlus sign icon
As of April 2026, Replicate Bioscience, Inc. has approximately 22 employees across 1 continents, including North America. Key team members include Chief Business Officer: K. F.Co-Founder: H. K. L.Scientific Director | Head Of Technology: S. M.. Explore Replicate Bioscience, Inc.'s employee directory with LeadIQ.

What industry does Replicate Bioscience, Inc. belong to?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc. operates in the Biotechnology Research industry.

What technology does Replicate Bioscience, Inc. use?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc.'s tech stack includes RSSWordPressJSON-LDScrollRevealPriority HintsWP EngineGoogle Tag ManagerNginx.

What is Replicate Bioscience, Inc.'s email format?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc.'s email format typically follows the pattern of FLast@replicatebioscience.com. Find more Replicate Bioscience, Inc. email formats with LeadIQ.

When was Replicate Bioscience, Inc. founded?

Minus sign iconPlus sign icon
Replicate Bioscience, Inc. was founded in 2020.

Replicate Bioscience, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Replicate Bioscience is amplifying the power of RNA therapeutics by pioneering novel self-replicating RNA (srRNA) technology. Replicate’s off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and the RNA encoding therapeutic proteins. Our library of viral vectors, selected for driving robust and sustained protein expression and orders-of-magnitude improved performance over linear mRNA, allow for the development of treatments in applications including oncology, infectious disease, and autoimmunity. 
Differentiated by a team of srRNA experts, a customizable library of synthetic srRNA vectors, and end-to-end development capabilities, Replicate is uniquely positioned to finally expand the reach of RNA treatments toward widespread use in infectious disease, immuno-oncology, autoimmune disease, and more.

Section iconCompany Overview

Headquarters
10210 Campus Point Drive #150 San Diego, California 92121 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $10M$25M

    Replicate Bioscience, Inc.'s revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    Replicate Bioscience, Inc.'s revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.